生物
病毒学
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
分离(微生物学)
2019-20冠状病毒爆发
中和抗体
抗体
计算生物学
免疫学
病毒
微生物学
传染病(医学专业)
爆发
医学
疾病
病理
作者
Megi Rexhepaj,Daniel Asarnow,Lisa Perruzza,Young‐Jun Park,Barbara Guarino,Mary McCallum,Katja Culap,Christian Saliba,Giada Leoni,Alessio Balmelli,Courtney Yoshiyama,Miles Sasha Dickinson,Joel Quispe,Jack T Brown,M. Alejandra Tortorici,Kaitlin R. Sprouse,Ashley Taylor,Davide Corti,Tyler N. Starr,Fabio Benigni
出处
期刊:Immunity
[Cell Press]
日期:2024-11-01
被引量:1
标识
DOI:10.1016/j.immuni.2024.10.001
摘要
Porcine delta-coronavirus (PDCoV) spillovers were recently detected in febrile children, underscoring the recurrent zoonoses of divergent CoVs. To date, no vaccines or specific therapeutics are approved for use in humans against PDCoV. To prepare for possible future PDCoV epidemics, we isolated PDCoV spike (S)-directed monoclonal antibodies (mAbs) from humanized mice and found that two, designated PD33 and PD41, broadly neutralized a panel of PDCoV variants. Cryoelectron microscopy (cryo-EM) structures of PD33 and PD41 in complex with the S receptor-binding domain (RBD) and ectodomain trimer revealed the epitopes recognized by these mAbs, rationalizing their broad inhibitory activity. We show that both mAbs competitively interfere with host aminopeptidase N binding to neutralize PDCoV and used deep-mutational scanning epitope mapping to associate RBD antigenic sites with mAb-mediated neutralization potency. Our results indicate a PD33-PD41 mAb cocktail may heighten the barrier to escape. PD33 and PD41 are candidates for clinical advancement against future PDCoV outbreaks.
科研通智能强力驱动
Strongly Powered by AbleSci AI